Disopyramide

h3292 · H 3292 · sc7031 · H. 3292 · Lispine · SC 7031 · Isorythm · Ritmodan

식별자 및 물리적 특성

CAS No.	22059-60-5
분자식	C21H29N3O
평균 분자량	339.5 g/mol
단동위원소 질량	339.23106256 g/mol
SMILES	CC(C)N(CCC(C(N)=O)(c1ccccc1)c1ccccn1)C(C)C
InChIKey	UVTNFZQICZKOEM-UHFFFAOYSA-N
PubChem CID	3114
ChEMBL	CHEMBL517
ChEBI	CHEBI:4657
EC No.	223-110-2
DTXSID	DTXSID1045536

화학 및 물리적 성질

XLogP	3.2
극성 표면적	59.2
수소 결합 공여자 수	1
수소 결합 수용자 수	3
회전 가능 결합 수	8
무거운 원자 수	25
형식 전하	0
복잡도	409
LogP(분배 계수)	3.52.71
용해도	4.93e-02 g/LDMSO(25mg/ml) 및 에탄올(>35mg/mL)에 용해됨
Human Drugs	Breast FeedingLactationMilk, HumanAntiarrhythmicsPharmaceuticals
녹는점	94.5-95 °C94.5 - 95 °C94.5-950C
Physical Description	Solid
Dissociation Constants	10.32
Collision Cross Section	183.45 Å² [M+K]+ [CCS Type: TWMethod: calibrated with polyalanine and drug standards]
끓는 점	475.43°C (rough estimate)
밀도	1.0779 (rough estimate)
굴절률	1.6300 (estimate)
저장 조건	Inert atmosphere,Room Temperature
물리적 상태	고체
pKa(산도 계수)	10.2also reported as 10.45(at 25℃)
색상	하얀색
용해도	6.17mg/L(22.5℃)
Merck	14,3360
안정성	제공된 대로 구매일로부터 1년 동안 안정적입니다. DMSO 또는 에탄올 용액은 -20°C에서 최대 1개월 동안 보관할 수 있습니다.
주요 응용	의약품(소분자)
InChI	1S/C21H29N3O/c1-16(2)24(17(3)4)15-13-21(20(22)25,18-10-6-5-7-11-18)19-12-8-9-14-23-19/h5-12,14,16-17H,13,15H2,1-4H3,(H2,22,25)
InChIKey	UVTNFZQICZKOEM-UHFFFAOYSA-N
SMILES	CC(C)N(CCC(C(N)=O)(c1ccccc1)c2ccccn2)C(C)C

화학적 성질

Crystalline Solid

안전 및 규제

Effects During Pregnancy and Lactation
GHS 분류	WarningH302 (100%): Harmful if swallowed [Warning Acute toxicity, oral]P203, P264, P270, P280, P301+P317, P318, P330, P405, and P501 (click each P-code to see the statement)Aggregated GHS information provided per 42 reports by companies from 4 notifications to the ECHA C&L Inventory. Each notification may be associated with multiple companies.
규제 정보	REACH registered substance: Disopyramide (EC: 223-110-2)Disopyramide: Does not have an individual approval but may be used under an appropriate group standard
기타 안전 정보	IMAP assessments - 2-Pyridineacetamide, .alpha.-[2-[bis(1-methylethyl)amino]ethyl]-.alpha.-phenyl-: Environment tier I assessment
Hazard Classes and Categories	Acute Tox. 4 (100%)
Hepatotoxicity	In clinical trials, disopyramide was associated with a low rate of serum aminotransferase and alkaline phosphatase elevations. Despite wide scale use, disopyramide has only rarely been linked to cases of clinically apparent liver injury. Two types of hepatic injury have been described. The first is an acute hepatocellular injury that arises within 1 to 3 days of starting disopyramide and resembles acute hepatic ischemia with marked early rises in serum aminotransferase levels (and LDH), with minimal increase in alkaline phosphatase and subsequent rise in serum bilirubin. The prothrombin time may be abnormal initially. The injury resolves rapidly and may relate to sudden worsening of congestive heart failure due to the myocardial depressant effects of disopyramide.
유해 작용	The most serious adverse reactions identified include hypotension and congestive heart failure. Common adverse reactions, which may be dose-dependent, are linked to the drug's anticholinergic properties. Although these effects can be transitory, they may also persist or become severe.
독성 요약	Signs and Symptoms of Overdose
Drug Induced Liver Injury	Drug-Induced Liver Injury Severity and Toxicity (DILIst)disopyramideDILI PositiveOralDOI:10.1016/j.drudis.2019.09.022

용도

개요

Structurally, disopyramide does not belong to any of the known classes of antiarrhythmics; however, being a drug of the class IA sodium channel blockers, it exhibits membranestabilizing action and increases the effective refractory period and duration of an action potential in the atrium and ventricles. It causes a decrease in contractability and excitability of the myocardium, slowing of conductivity, and suppression of sinoatride automatism.

용도

Disopyramide is used for preventing and restoring atrial and ventricular extrasystole and tachycardia in order to prevent atrial flutter and arrhythmia.